Commentary regarding: A randomized trial of icatibant in ACE‐inhibitor‐induced angioedema

K. Yancey

DOI: https://doi.org/10.1111/dth.12236

2015-09-01

Dermatologic Therapy

Abstract:Angiotensin-converting-enzyme (ACE) inhibitorinduced angioedema is thought to account for approximately one-third of angioedema cases seen in emergency rooms. Angioedema induced by ACE inhibitors usually affects the upper airway in the head and neck region (although in rare cases, the gastrointestinal tract can be affected as well). In a multicenter, double-blind, randomized phase 2 study, Bas et al. assigned 30 patients with ACEinhibitor-induced angioedema of the upper aerodigestive tract to receive treatment with 30 mg of icatibant (a selective bradykinin B2 receptor antagonist), or standard off-label therapy (i.e., prednisolone 500 mg IV plus clemastine 2 mg) (1). Of note, treatment was administered to three patients before randomization; these patients were excluded from the formal analysis, thus leaving a subject number of 27. All 27 of these patients had complete resolution of angioedema following treatment. The median time to complete resolution was 8 hours with icatibant versus 27.1 hours with standard off-label therapy. More patients in the icatibant group had complete resolution of angioedema 4 hours after treatment (5 of 12 vs. 0 of 14 in the standard therapy group). Moreover, the median time to onset of symptom relief (based on a composite investigator-assessed [and a separate patient-assessed] symptom score) was significantly shorter with icatibant than with standard therapy (2 vs. 11.7 hours in respect to the investigator-assessed symptom score). Three patients in the standard therapy group required rescue therapy (i.e., icatibant and prednisolone [plus tracheostomy in one patient]). While the role of bradykinin in ACE-inhibitor-induced angioedema is yet to be precisely defined, ACE is deemed to be an important enzyme regulating the breakdown of bradykinin in plasma and tissue. Moreover, prior studies in animals and humans have shown that blockade of bradykinin B2 receptors attenuates the efficacy of ACE inhibitors. Icatibant represents a logical treatment for ACE-inhibitor-induced angioedema – an intervention substantiated in this study.